Therapeutic Area

Combination Therapy

Therapeutic area intelligence for Combination Therapy with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 2

Companies

AstraZeneca →

Bristol Myers Squibb →

Assets

INQOVI →

OPDUALAG →

Selumetinib →

Recent signals(3)

RegulatoryJune 21, 2026

FDA Accepts Supplement for INQOVI by Taiho Oncology

The FDA has accepted a supplemental application for INQOVI (NDA212576) from Taiho Oncology.

RegulatoryJune 21, 2026

FDA Accepts Supplemental Application for OPDUALAG by Bristol Myers Squibb

The FDA has accepted a supplemental application for OPDUALAG, a combination of nivolumab and relatlimab-rmbw.

ClinicalJune 18, 2026

Phase II Trial of Selumetinib and Olaparib in RAS Pathway Mutant Ovarian and Endometrial Cancers

A phase II trial is comparing the efficacy of selumetinib plus olaparib versus selumetinib alone in patients with RAS pathway mutant recurrent or persistent ovarian and endometrial cancers.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.